TY - JOUR
T1 - Rhinology Future Debates 2017 by EUFOREA
T2 - Novel treatments and surgical solutions in rhinology
AU - Fokkens, Wytske J
AU - Pugin, Benoit
AU - Bachert, Claus
AU - Bousquet, Jean
AU - Joos, Guy
AU - Louis, Renaud
AU - Pilette, Charles
AU - Pfaar, Oliver
AU - Price, David
AU - Prokopakis, Emmanuel
AU - Scadding, Glenis
AU - Strzembosz, Agnieszka
AU - Weilandt, Anders
AU - Seys, Sven
AU - Hellings, Peter W
N1 - This article is protected by copyright. All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - The second Rhinology Future Debates organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. These debates aim at bringing novel developments in the field of Rhinology to the attention of the medical, paramedical and patient community, in a credible and balanced context. Novel developments are presented by key experts from industry and/or key opinion leaders, and are followed by a lively debate on the potential positioning of new developments in care pathways, the strengths and weaknesses of the novel development(s), and comparisons with existing and/or competing products, devices, and/or molecules. Debate topics presented here include: i) Real World Evidence data in AIT - What does it bring to us?, ii) Nasal turbinate as therapeutic target in patients with turbinate-induced nasal symptoms, and iii) Lessons from biologicals in asthma for ENT physicians. As all debates are recorded and distributed on-line with limited editing (www.rhinology-future.com), EUFOREA aims at maximizing the education on novel developments, allowing a critical appraisal of the future and a more rapid implementation of promising novel tools, techniques and/or molecules in clinical practise. The next Rhinology Future Debate will be in held in 2018. This article is protected by copyright. All rights reserved.
AB - The second Rhinology Future Debates organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. These debates aim at bringing novel developments in the field of Rhinology to the attention of the medical, paramedical and patient community, in a credible and balanced context. Novel developments are presented by key experts from industry and/or key opinion leaders, and are followed by a lively debate on the potential positioning of new developments in care pathways, the strengths and weaknesses of the novel development(s), and comparisons with existing and/or competing products, devices, and/or molecules. Debate topics presented here include: i) Real World Evidence data in AIT - What does it bring to us?, ii) Nasal turbinate as therapeutic target in patients with turbinate-induced nasal symptoms, and iii) Lessons from biologicals in asthma for ENT physicians. As all debates are recorded and distributed on-line with limited editing (www.rhinology-future.com), EUFOREA aims at maximizing the education on novel developments, allowing a critical appraisal of the future and a more rapid implementation of promising novel tools, techniques and/or molecules in clinical practise. The next Rhinology Future Debate will be in held in 2018. This article is protected by copyright. All rights reserved.
KW - Letter
U2 - 10.1111/coa.13184
DO - 10.1111/coa.13184
M3 - Article
C2 - 29989349
VL - 43
SP - 1429
EP - 1438
JO - Clinical Otolaryngology
JF - Clinical Otolaryngology
SN - 1749-4478
IS - 6
ER -